PL2019965T3 - Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego - Google Patents

Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego

Info

Publication number
PL2019965T3
PL2019965T3 PL07761742T PL07761742T PL2019965T3 PL 2019965 T3 PL2019965 T3 PL 2019965T3 PL 07761742 T PL07761742 T PL 07761742T PL 07761742 T PL07761742 T PL 07761742T PL 2019965 T3 PL2019965 T3 PL 2019965T3
Authority
PL
Poland
Prior art keywords
pulmonary
cardiovascular disease
differential diagnosis
diagnosis
differential
Prior art date
Application number
PL07761742T
Other languages
English (en)
Inventor
James V Snider
Sven Jacobson
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of PL2019965T3 publication Critical patent/PL2019965T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
PL07761742T 2006-05-02 2007-05-02 Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego PL2019965T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79728506P 2006-05-02 2006-05-02
PCT/US2007/068024 WO2007131031A2 (en) 2006-05-02 2007-05-02 Diagnosis of pulmonary and/or cardiovascular disease
EP07761742.1A EP2019965B1 (en) 2006-05-02 2007-05-02 Differential diagnosis between pulmonary and cardiovascular disease

Publications (1)

Publication Number Publication Date
PL2019965T3 true PL2019965T3 (pl) 2015-10-30

Family

ID=38668508

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07761742T PL2019965T3 (pl) 2006-05-02 2007-05-02 Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego

Country Status (9)

Country Link
US (2) US20100055683A1 (pl)
EP (2) EP2995951B1 (pl)
DK (1) DK2019965T3 (pl)
ES (2) ES2723957T3 (pl)
HU (1) HUE025058T2 (pl)
PL (1) PL2019965T3 (pl)
PT (1) PT2019965E (pl)
SI (1) SI2019965T1 (pl)
WO (1) WO2007131031A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
HUE027779T2 (en) 2002-05-09 2016-11-28 Brigham & Womens Hospital Inc 1L1RL-1 is a marker of cardiovascular disease
WO2007127749A2 (en) 2006-04-24 2007-11-08 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
EP2021799B1 (en) * 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
AU2007248160B2 (en) 2006-05-01 2011-03-24 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
PL2019965T3 (pl) * 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
EP1882945A1 (en) * 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Means and methods for the differentiation of cardiac and pulmonary causes of acute shortness of breath
HUE039963T2 (hu) 2008-04-18 2019-02-28 Critical Care Diagnostics Inc Súlyos káros szívesemények rizikójának elõrejelzése
EP2141499A1 (en) * 2008-07-02 2010-01-06 Apoptec AG COPD diagnosis
WO2010017972A1 (en) * 2008-08-13 2010-02-18 Roche Diagnostics Gmbh D-dimer, troponin, nt-probnp for pulmonary embolism
MX360543B (es) * 2010-04-09 2018-10-24 Critical Care Diagnostics Inc Anticuerpos st-2 humanos solubles y ensayos.
CN106940375B (zh) 2011-03-17 2019-03-08 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
JP6134316B2 (ja) 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
AU2013262515B2 (en) 2012-05-18 2018-03-15 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
ES2656897T3 (es) * 2012-08-16 2018-02-28 Critical Care Diagnostics, Inc. Procedimientos de predicción del riesgo de desarrollar hipertensión
JP6450679B2 (ja) 2012-08-21 2019-01-09 クリティカル ケア ダイアグノスティクス インコーポレイテッド マルチマーカーリスク層別化
JP6655016B2 (ja) 2014-01-10 2020-02-26 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心不全のリスクを決定するための方法
EP3218515B1 (en) 2014-11-10 2023-04-26 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for il-33-mediated disorders
EP3783023A1 (en) 2014-11-10 2021-02-24 H. Hoffnabb-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
KR101873499B1 (ko) * 2015-02-10 2018-07-03 주식회사 원메디칼 혈관 질환 진단용 바이오 마커 및 이의 용도
CN110573174A (zh) * 2017-02-17 2019-12-13 通用医疗公司 用于治疗脑损伤的方法和组合物
US20190120788A1 (en) * 2017-10-20 2019-04-25 University Of Southern California Systems and methods for fabricating an indium oxide field-effect transistor
CN109633138A (zh) * 2019-01-24 2019-04-16 黑龙江八农垦大学 一种预警奶牛胎衣不下的生物标志物及其应用
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534879A (en) * 1895-02-26 Device foe packing
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5217899A (en) * 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
EP1493439B1 (en) * 1997-04-02 2011-10-26 The Brigham And Women's Hospital, Inc. Means of ascertaining an individual' s risk profile for atherosclerotic disease
WO1998057179A1 (en) * 1997-06-10 1998-12-17 Medlyte Diagnostics, Inc. Methods for early detection of heart disease
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
FR2795823B1 (fr) * 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
US7432060B2 (en) * 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
ATE458199T1 (de) * 2001-05-04 2010-03-15 Biosite Inc Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
HUE027779T2 (en) * 2002-05-09 2016-11-28 Brigham & Womens Hospital Inc 1L1RL-1 is a marker of cardiovascular disease
US20070042978A1 (en) * 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
US20040133079A1 (en) * 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
WO2005042795A2 (en) 2003-10-31 2005-05-12 Queststar Medical, Inc. Plasma polymerization of atomically modified surfaces
EP2386658B1 (en) * 2003-11-26 2014-01-08 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2007127749A2 (en) * 2006-04-24 2007-11-08 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
AU2007248160B2 (en) * 2006-05-01 2011-03-24 Critical Care Diagnostics, Inc. Diagnosis of cardiovascular disease
PL2019965T3 (pl) * 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
US8147817B2 (en) * 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
HUE039963T2 (hu) * 2008-04-18 2019-02-28 Critical Care Diagnostics Inc Súlyos káros szívesemények rizikójának elõrejelzése
MX360543B (es) * 2010-04-09 2018-10-24 Critical Care Diagnostics Inc Anticuerpos st-2 humanos solubles y ensayos.
CN106940375B (zh) * 2011-03-17 2019-03-08 重症监护诊断股份有限公司 预测不良临床结果的风险的方法
JP6134316B2 (ja) * 2011-07-18 2017-05-24 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心臓血管疾患を治療する方法および運動療法の有効性を予測する方法

Also Published As

Publication number Publication date
PT2019965E (pt) 2015-08-28
SI2019965T1 (sl) 2015-10-30
DK2019965T3 (en) 2015-07-20
ES2723957T3 (es) 2019-09-04
ES2542343T3 (es) 2015-08-04
EP2019965A4 (en) 2009-12-16
HUE025058T2 (en) 2016-01-28
US20100055683A1 (en) 2010-03-04
EP2019965B1 (en) 2015-04-15
WO2007131031A2 (en) 2007-11-15
EP2019965A2 (en) 2009-02-04
EP2995951B1 (en) 2019-02-13
US20140302536A1 (en) 2014-10-09
EP2995951A1 (en) 2016-03-16
WO2007131031A3 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
SI2019965T1 (sl) Diferencialna diagnoza med pljučno boleznijo in boleznijo srca in ožilja
IL188231A0 (en) Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
IL187859A0 (en) Diagnosis and prognosis of diabetes
EP1888765A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
PL1885383T3 (pl) Kocie probiotyczne bifidobakterie
EP2019911A4 (en) PULMONARMATRATZE
EP2090098A4 (en) COLLECTING AND ANALYZING DATA FROM SPECIALIST EXPERTS
EP1970002A4 (en) CUFF OF A BLOOD PRESSURE METER AND BLOOD PRESSURE METER THEREFOR
ZA201000983B (en) Methods and compositions for diagnosing disease
ZA201001486B (en) Diagnosis,staging and monitoring of inflammatory bowel disease
GB2430045B (en) Multi-spectral imaging
IL172754A0 (en) Urethral blockage diagnosis
EP2153345A4 (en) PROVISION OF ROUTE INFORMATION BETWEEN VARIOUS APPLICATION INFORMATION AND USE OF THE ROUTE INFORMATION
EP2086383A4 (en) CAPSULE TYPE ENDOSCOPE
IL184343A0 (en) Gitr antibodies for the diagnosis of nsclc
PL2056858T3 (pl) Leczenie stanów chorobowych płuc
GB0815846D0 (en) diagnosis, prognosis and imaging of disease
FR2916969B1 (fr) Kit comprenant des composes x et y fonctionnalises alcoxysilane.
GB0709092D0 (en) Diagnosis and method of disease
EP1870710A4 (en) BIOMARKERS FOR DIAGNOSIS OF DISEASE AND USE THEREOF
GB0900296D0 (en) Air cleaner and air cleaner diagnostic process
GB2415039B (en) Diagnosis and prognosis
FR2916970B1 (fr) Kit comprenant des composes x et y fonctionnalises alpha-alcoxysilane.
GB0613113D0 (en) Nanotubes and nanotube micelles
EP2057570A4 (en) MONITORING CLINICAL DATA